<SEC-DOCUMENT>0001193125-23-252361.txt : 20231006
<SEC-HEADER>0001193125-23-252361.hdr.sgml : 20231006
<ACCEPTANCE-DATETIME>20231006160104
ACCESSION NUMBER:		0001193125-23-252361
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231006
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231006
DATE AS OF CHANGE:		20231006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		231314204

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d534754d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20231006" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2023-10-06_to_2023-10-06" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-06_to_2023-10-06">0000318154</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2023-10-06_to_2023-10-06" name="dei:AmendmentFlag" contextRef="duration_2023-10-06_to_2023-10-06">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20231006.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-06_to_2023-10-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-06_to_2023-10-06">8-K</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p><p style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-06_to_2023-10-06" format="ixt:date-monthname-day-year-en">October&#160;6, 2023</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityRegistrantName">Amgen Inc.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityFileNumber">001-37702</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityTaxIdentificationNumber">95-3540776</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-06_to_2023-10-06">One Amgen Center Drive</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-06_to_2023-10-06">Thousand Oaks</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-06_to_2023-10-06" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-06_to_2023-10-06">91320-1799</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table><p style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code:</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:CityAreaCode">805</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:LocalPhoneNumber">447-1000</ix:nonNumeric></span></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed since Last Report)</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities Registered under Section 12(b) of the Act:</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter). Emerging growth company <ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&#160;</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introductory Note</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;6, 2023, Amgen Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;), Horizon Therapeutics plc, a public limited company incorporated under the laws of Ireland (&#8220;<span style="text-decoration:underline">Horizon</span>&#8221;), and Pillartree Limited, a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of Amgen (&#8220;<span style="text-decoration:underline">Acquirer Sub</span>&#8221;), completed the transactions contemplated by that certain Transaction Agreement (the &#8220;<span style="text-decoration:underline">Transaction Agreement</span>&#8221;), dated as of December&#160;11, 2022, by and among Amgen, Horizon and Acquirer Sub. Pursuant to a court-sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the &#8220;<span style="text-decoration:underline">Scheme</span>&#8221;), Acquirer Sub acquired the entire issued ordinary share capital of Horizon (the &#8220;<span style="text-decoration:underline">Acquisition</span>&#8221;) and Horizon became a wholly-owned subsidiary of Amgen.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;2.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Completion of Acquisition or Disposition of Assets.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Acquisition was conditioned on, among other things, the sanction of the Scheme by the Irish High Court (the &#8220;<span style="text-decoration:underline">Court</span>&#8221;) and the delivery of the Court Order (as defined in the Transaction Agreement) to the Registrar of Companies in Dublin, Ireland. On October&#160;5, 2023, the Court sanctioned the Scheme. On October&#160;6, 2023, the Court Order was delivered to the Registrar of Companies, at which time the Scheme became effective (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">At the Effective Time, Acquirer Sub acquired all of the outstanding ordinary shares of Horizon of nominal value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Ordinary Shares</span>&#8221;) other than Ordinary Shares held by Horizon or its subsidiaries (such acquired Ordinary Shares, collectively, the &#8220;<span style="text-decoration:underline">Horizon Shares</span>&#8221;) and each holder of Horizon Shares outstanding as of 11:59 p.m. New York City time on October&#160;5, 2023, the business day prior to the occurrence of the Effective Time (the &#8220;<span style="text-decoration:underline">Scheme Record Time</span>&#8221;), obtained the right to receive $116.50 in cash in exchange for each Horizon Share (the &#8220;<span style="text-decoration:underline">Consideration</span>&#8221;). In respect of the Horizon Shares issued and outstanding as of the Scheme Record Time, Amgen paid an aggregate of approximately $26.7 billion in cash to former shareholders of Horizon.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Transaction Agreement, at the Effective Time, each outstanding equity award with respect to Horizon Shares (other than certain restricted stock unit awards denominated in Horizon Shares (&#8220;<span style="text-decoration:underline">Horizon RSUs</span>&#8221;)) was, whether vested or unvested, cancelled and converted into the right to receive the Consideration (less the applicable exercise price in the case of options). Other than any Horizon RSUs granted to <span style="white-space:nowrap">non-employee</span> directors or former service-providers of Horizon as of the completion date for the Acquisition (which Horizon RSUs were canceled and converted into the right to receive the product of the Consideration, <span style="font-style:italic">multiplied</span> by the total number of Horizon Shares subject to such Horizon RSUs immediately prior to the Effective Time), all Horizon RSUs were assumed by Amgen and converted into restricted stock units (each, an &#8220;<span style="text-decoration:underline">Amgen RSU</span>&#8221;) denominated in shares of common stock of Amgen, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">Amgen Common Stock</span>&#8221;), with the number of shares of Amgen Common Stock subject to each such Amgen RSU equal to the product (rounded down to the nearest whole number) of (i)&#160;the number of Horizon Shares subject to such Horizon RSUs immediately prior to the Effective Time <span style="font-style:italic">multiplied</span> by (ii)&#160;(x)&#160;the Consideration divided by (y)&#160;the volume weighted average of the per share closing price of Amgen Common Stock on the Nasdaq Global Select Market (as reported in the Eastern Edition of <span style="font-style:italic">The Wall Street Journal</span> or, if not reported thereby, another authoritative source) for five trading days ending on the second business day prior to the completion of the Acquisition.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">In connection with the completion of the Acquisition, trading of the Horizon Shares on the Nasdaq Global Select Market (the &#8220;<span style="text-decoration:underline">Nasdaq</span>&#8221;) was halted and the Horizon Shares will be delisted from the Nasdaq. Pursuant to the terms of the Transaction Agreement, Amgen and Horizon will take steps to cause the Horizon Shares to be deregistered under the Securities Exchange Act of 1934 (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;) as promptly as practicable following the Effective Time.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing descriptions of the Transaction Agreement and Appendix 3 to the Rule 2.7 Announcement (the &#8220;<span style="text-decoration:underline">Conditions Appendix</span>&#8221;) do not purport to be complete and are subject to, and qualified in their entireties by, the full text of the Transaction Agreement and the Conditions Appendix, which were filed as Exhibit 2.1 and Exhibit 2.2, respectively, to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022, and are incorporated by reference into this Item 2.01.</p><p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-1-</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;2.03</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Creation of a Direct Financial Obligation or an Obligation Under an <span style="white-space:nowrap">Off-</span> Balance Sheet Arrangement of a Registrant.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">As previously reported, on December&#160;22, 2022, Amgen entered into a Term Loan Credit Agreement (the &#8220;<span style="text-decoration:underline">Term Loan Credit Agreement</span>&#8221;) among Amgen, Citibank, N.A. (&#8220;<span style="text-decoration:underline">Citibank</span>&#8221;), as administrative agent, Bank of America, N.A. (&#8220;<span style="text-decoration:underline">Bank of America</span>&#8221;), as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents. On October&#160;6,&#160;2023, Amgen borrowed $4&#160;billion under the Term Loan Credit Agreement to fund a portion of the Consideration paid to Horizon shareholders and to pay other funding obligations and fees in connection with the Acquisition.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The description of the Term Loan Credit Agreement contained in this Item 2.03 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Term Loan Credit Agreement, which was filed as Exhibit 10.1 to Amgen&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on December&#160;22, 2022 and is incorporated by reference into this Item 2.03.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Regulation FD Disclosure.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;6, 2023, Amgen issued a press release announcing the successful completion of the Acquisition. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 7.01.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:96%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex21.htm">Transaction Agreement, dated as of December&#160;11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc., incorporated by reference to Exhibit&#160;2.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022.</a>*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex22.htm">Appendix 3 to the Rule 2.7 Announcement, dated as of December&#160;12, 2022 (Conditions Appendix), incorporated by reference to Exhibit&#160;2.2 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022</a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d534754dex991.htm">Press Release, dated October&#160;6, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</p><p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2-</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">&#8195;&#8195;&#8195;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">AMGEN INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;6, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan P. Graham</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jonathan P. Graham</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and General Counsel and Secretary</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d534754dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1&#8195;&#8195;&#8195;&#8195;&#8195; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">


<IMG SRC="g534754sp001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:30pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Thousand&nbsp;Oaks,&nbsp;CA&nbsp;91320-1799</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">www.Amgen.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL">&#8201;<B><I>News Release</I></B> </P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>AMGEN COMPLETES ACQUISITION OF HORIZON
THERAPEUTICS PLC </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Advances Amgen&#146;s Mission to Serve Patients With
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> Rare Disease Medicines </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">THOUSAND OAKS, Calif.
(Oct. 6,&nbsp;2023) &#150; Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8&nbsp;billion. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world
suffering from serious illnesses,&#148; said Robert A. Bradway, Amgen&#146;s chairman and chief executive officer. &#147;We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a
broader range of diseases.&#148; </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">The compelling strategic and financial rationale for the acquisition includes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Alignment with Amgen&#146;s core strategy of delivering innovative medicines that make a significant difference for
patients suffering from serious diseases. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Strengthening of Amgen&#146;s leading inflammation portfolio by adding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-in-lifecycle</FONT></FONT> medicines such as TEPEZZA&reg; (teprotumumab-trbw), KRYSTEXXA&reg; (pegloticase) and
UPLIZNA&reg; (inebilizumab-cdon), which treat rare inflammatory diseases. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Leveraging of Amgen&#146;s world-class capabilities in biologics research and development, process development and
manufacturing, as well as Amgen&#146;s presence in more than 100 countries around the world. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Generating robust cash flow to support capital allocation priorities, including ongoing investment in innovation while
sustaining a commitment to an investment grade credit rating. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Acceleration of revenue growth; expected to be accretive to <FONT STYLE="white-space:nowrap">non-GAAP</FONT> earnings per
share from 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen expects to provide updated FY 2023 guidance during its third quarter earnings call. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About TEPEZZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (teprotumumab-trbw) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 2
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
</P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>TEPEZZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (teprotumumab-trbw) Important Safety Information </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>WARNINGS AND PRECAUTIONS </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Infusion Reactions </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have
usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Preexisting Inflammatory Bowel Disease </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">TEPEZZA may cause an exacerbation of
preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Hyperglycemia </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Increased blood glucose or hyperglycemia may occur in patients
treated with TEPEZZA. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Hearing Impairment including Hearing Loss </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">TEPEZZA
may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients&#146; hearing before, during and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Please see&nbsp;<FONT STYLE="font-family:ARIAL" COLOR="#4076ba">Full Prescribing Information</FONT>&nbsp;or
visit&nbsp;<FONT STYLE="font-family:ARIAL" COLOR="#4076ba">TEPEZZAhcp.com</FONT>&nbsp;for more information. </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About KRYSTEXXA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegloticase) </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>KRYSTEXXA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pegloticase)
Indication </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">KRYSTEXXA&nbsp;(pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose
signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>KRYSTEXXA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegloticase) Important Safety Information </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>WARNING: ANAPHYLAXIS AND INFUSION REACTIONS, G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 3
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Anaphylaxis may occur with any infusion, including a first infusion and generally manifests within 2 hours of the infusion.
Delayed hypersensitivity reactions have also been reported. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and
infusion reactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Patients should be premedicated with antihistamines and corticosteroids and closely monitored for anaphylaxis for an
appropriate period after administration of KRYSTEXXA. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Serum uric acid levels should be monitored prior to each infusion and treatment discontinued if levels increase to above 6
mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Patients at risk for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">glucose-6-phosphate</FONT></FONT>
dehydrogenase (G6PD) deficiency should be screened prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXA is contraindicated in patients with G6PD deficiency.
</P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>CONTRAINDICATIONS </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">In patients with G6PD deficiency. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">In patients with history of serious hypersensitivity reactions, including anaphylaxis, to KRYSTEXXA or any of its
components. </P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>WARNINGS AND PRECAUTIONS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Gout
Flares:</B>&nbsp;An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drug (NSAID)
or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Congestive Heart Failure:</B>&nbsp;KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the <FONT
STYLE="white-space:nowrap">pre-marketing</FONT> placebo-controlled clinical trials experienced exacerbation. Caution should be exercised in patients who have congestive heart failure and patients should be closely monitored following infusion. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Please see&nbsp;<FONT STYLE="font-family:ARIAL" COLOR="#0000ff"><U>Full Prescribing Information</U></FONT>,&nbsp;including Boxed Warning. </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About UPLIZNA<SUP STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (inebilizumab-cdon) </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are
<FONT STYLE="white-space:nowrap">anti-aquaporin-4</FONT> (AQP4) antibody positive. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>UPLIZNA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(inebilizumab-cdon) Important Safety Information </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">UPLIZNA is contraindicated in patients with: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">A history of life-threatening infusion reaction to UPLIZNA </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Active hepatitis B infection </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Active or untreated latent tuberculosis </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 4
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>WARNINGS AND PRECAUTIONS </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Infusion Reactions </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">UPLIZNA can cause infusion reactions, which can include
headache, nausea, somnolence, dyspnea, fever, myalgia, rash or other symptoms. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Infections </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%),
upper respiratory tract infection (8%) and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">The
risk of Hepatitis B Virus (HBV) reactivation has been observed with other <FONT STYLE="white-space:nowrap">B-cell-depleting</FONT> antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to
patients with active hepatitis. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC
virus infection resulting in PML has been observed in patients treated with other <FONT STYLE="white-space:nowrap">B-cell-depleting</FONT> antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML,
withhold UPLIZNA and perform an appropriate diagnostic evaluation. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until <FONT STYLE="white-space:nowrap">B-cell</FONT>
repletion. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Reduction in Immunoglobulins </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">There may be a progressive and
prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>For additional information on UPLIZNA, please see the Full Prescribing Information
at&nbsp;<FONT STYLE="font-family:ARIAL" COLOR="#0000ff"><U>www.UPLIZNA.com</U></FONT>. </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About&nbsp;Amgen</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen&nbsp;is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen&nbsp;focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically
improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#146;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines
with breakaway potential. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 5
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the
<FONT STYLE="white-space:nowrap">Nasdaq-100</FONT> index. In 2023, Amgen was named one of &#147;America&#146;s Greatest Workplaces&#148; by Newsweek, one of &#147;America&#146;s Climate Leaders&#148; by USA Today and one of the &#147;World&#146;s
Best Companies&#148; by TIME. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">For more information, visit <FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>Amgen.com</U></FONT><FONT
STYLE="font-family:ARIAL"> and follow us on </FONT><FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>X</U></FONT><FONT STYLE="font-family:ARIAL"> (formerly known as Twitter), </FONT><FONT
STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>LinkedIn</U></FONT><FONT STYLE="font-family:ARIAL">, </FONT><FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>Instagram</U></FONT><FONT STYLE="font-family:ARIAL">, </FONT><FONT
STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>TikTok</U></FONT><FONT STYLE="font-family:ARIAL">, </FONT><FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>YouTube</U></FONT><FONT STYLE="font-family:ARIAL"> and </FONT><FONT
STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>Threads</U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About Horizon </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people
impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to
transform lives. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Amgen Forward-Looking Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene,
Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (apremilast) (including anticipated Otezla sales growth and the timing of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS
accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc acquisition (including the prospective performance and outlook of Horizon&#146;s business, performance and opportunities and any
potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political,
regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates
and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent periodic reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and current reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Unless otherwise noted, Amgen is
providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our
ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products
including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 6
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">reimbursement policies imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and
other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on
the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to
meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection
offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial
manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product
candidate development. An outbreak of disease or similar public health threat, such as <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the public and governmental effort to mitigate against the spread of such disease, could have a significant
adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect
on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial
products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will
be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial
purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and
on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be
successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than
expected. We may not be able to successfully integrate Horizon, and such acquisition or integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology
systems could compromise the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Page&#8201;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6e6e6">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#e6e6e6"><FONT STYLE="font-size:10pt" COLOR="#2b579a">
 7
</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">confidentiality, integrity and availability of our systems and our data. Our stock price is volatile
and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and
related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to
declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">#&#8201;#&#8201;#</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">CONTACT: Amgen, Thousand Oaks</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Jessica Akopyan, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-440-5721</FONT></FONT> (media)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Justin Claeys, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-313-9775</FONT></FONT> (investors) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20231006.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.0 -->
<!-- Creation date: 10/6/2023 3:37:39 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:amgn="http://www.amgen.com/20231006"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20231006"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231006_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231006_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231006_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_A2.00SeniorNotesDue2026Member" name="A2.00SeniorNotesDue2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20231006_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.0 -->
<!-- Creation date: 10/6/2023 3:37:41 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20231006.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="amgn-20231006.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntitiesTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="32.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="44.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20231006_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.0 -->
<!-- Creation date: 10/6/2023 3:37:40 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="amgn-20231006.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A2.00SeniorNotesDue2026Member" xlink:to="amgn_A2.00SeniorNotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.00% Senior Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20231006_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.0 -->
<!-- Creation date: 10/6/2023 3:37:40 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20231006.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitiesTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_EntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20231006.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g534754sp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g534754sp001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M '5_(T 'VZ7^ZOY&@ ^W2_W5_(T 'VZ7^ZOY&@ ^W2_W5_(T 'VZ7^ZOY&@
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M^;/0IXATL,XQW;_1'*Q12W$R11(TDKG"JHR2:]!M15WL<"3D[([.Q^&&LW,
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M*)ZF5_#(Y#QQI2Z3XIN8XAB*;$R#T#=?U!KTL!5=6@F]UH>?C:2I5FEL]1?
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M]10 ?9)_[GZB@ ^R3_W/U% !]DG_ +GZB@ ^R3_W/U% !]DG_N?J* #[)/\
MW/U% !]DG_N?J* #[)/_ '/U% !]DG_N?J* -.@ H * "@ H * "@ H * "@
? H * "@ H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140122047992512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  06,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes Due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d534754d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20231006"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20231006.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-06_to_2023-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-06_to_2023-10-06"
      id="Hidden_dei_EntityCentralIndexKey_duration_2023-10-06_to_2023-10-06">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2023-10-06_to_2023-10-06"
      id="Hidden_dei_AmendmentFlag_duration_2023-10-06_to_2023-10-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2023-10-06_to_2023-10-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-06_to_2023-10-06">2023-10-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-06_to_2023-10-06">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-06_to_2023-10-06">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-06_to_2023-10-06">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-06_to_2023-10-06">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-06_to_2023-10-06">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-06_to_2023-10-06">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-06_to_2023-10-06">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-06_to_2023-10-06">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-06_to_2023-10-06">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-06_to_2023-10-06">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-06_to_2023-10-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-06_to_2023-10-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-06_to_2023-10-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-06_to_2023-10-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-06_to_2023-10-06">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/UY_ 5!+ 0(4 Q0    ( "& 1E<'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (8!&5PX?TY/N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ (8!&5YE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  A@$974,]#.L4$   N%0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ (8!&5Y^@&_"Q @  X@P   T              ( !" T  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  A@$97EXJ[',     3 @  "P
M    @ 'D#P  7W)E;',O+G)E;'-02P$"% ,4    "  A@$97'#AEZC\!   \
M @  #P              @ '-$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ (8!&5R0>FZ*M    ^ $  !H              ( !.1(  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ (8!&5V60>9(9 0  SP,
M !,              ( !'A,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  :!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d534754d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amgn-20231006.xsd</File>
    <File>amgn-20231006_def.xml</File>
    <File>amgn-20231006_lab.xml</File>
    <File>amgn-20231006_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d534754d8k.htm">d534754d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d534754d8k.htm": {
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20231006",
   "dts": {
    "schema": {
     "local": [
      "amgn-20231006.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20231006_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20231006_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20231006_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d534754d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-06_to_2023-10-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d534754d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-06_to_2023-10-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d534754d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.amgen.com/20231006",
     "localname": "A2.00SeniorNotesDue2026Member",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.amgen.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-23-252361-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-252361-xbrl.zip
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MAMCDU0WN+6L$LU;S66GA7.E\ G-6"MR 4GXOF>!S#IGW @$Y2+OAL^EAF5Z
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MDF:I;;Z=AJMLJ^L$/W\ 4$L#!!0    ( "& 1E>D!7-0KP4  $HS   5
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M_HG[#(8R09UFTZFU#PZ:K87X>D5;C+8;.CF/PU6N>3?!87>OUM[K- \.]E=
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MB^'C,?.X%0TY"9[G'PQD@ 8OXH&"L!I;C]^*H!)\E'(*< &R) 9(UO8IS40
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M>G7VK)'/XL$!I$\NXX#):O>&[);=40%\,+45<9Z-EMH,=QS^5+!TF\G!1-2
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M_1:("2#H[. S?'DT.#G>_7]02P$"% ,4    "  A@$97=]=0X)$#  #^#
M$0              @ $     86UG;BTR,#(S,3 P-BYX<V102P$"% ,4
M"  A@$97I 5S4*\%  !*,P  %0              @ '  P  86UG;BTR,#(S
M,3 P-E]D968N>&UL4$L! A0#%     @ (8!&5SM&:"6D!P  (54  !4
M         ( !H@D  &%M9VXM,C R,S$P,#9?;&%B+GAM;%!+ 0(4 Q0    (
M "& 1E?WL,P57 4   \V   5              "  7D1  !A;6=N+3(P,C,Q
M,# V7W!R92YX;6Q02P$"% ,4    "  A@$97M8ZX/M88  #2FP  #@
M        @ $(%P  9#4S-#<U-&0X:RYH=&U02P$"% ,4    "  A@$97JW0D
MBQPB  !)H@  $0              @ $*,   9#4S-#<U-&1E>#DY,2YH=&U0
52P4&      8 !@"# 0  55(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
